Scoped author-reported evaluation; read protocol and cohort limits before comparing.
These checks assess whether the evidence supports a reproducible investigation. A source-checked score alone does not meet these requirements.
Release 2026-09-30-e37e3ab1284d · Evidence verified: Not verified
Exact outcomes, predictions, identifiers and evaluator are connected.
Missing or unresolved evidence
Verified: Not verified
Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.
Missing or unresolved evidence
Verified: Not verified
A pinned recipe describes the inputs, environment and resource requirements.
Missing or unresolved evidence
Verified: Not verified
Separate data and exposure records support an independent test.
Missing or unresolved evidence
Verified: Not verified
Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.
No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.
1 evaluation · 8 results. Different protocols are not a single leaderboard.
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 43% benign_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, benign_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 78% concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 78.2% missense_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, missense_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 82.5% oncogene_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogene_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 79% oncogenic_vs_pathogenic_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogenic_vs_pathogenic_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 49.4% truncating_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, truncating_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 76% tsg_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, tsg_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 97% vus_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, vus_concordance; subgroup values correspond to Supplemental Table S6 |
Source checking is not independent reproduction. Release 2026-09-30-e37e3ab1284d.
Not reported
Metadata review: source checked. Unreported conditions prevent automatic comparisons.
No execution recipe has been verified for this exact configuration and evaluation. A benchmark's general instructions may use different inputs, splits or model settings.
Reproducing this published result requires matching its model configuration, data, split and scorer. Source checking or a successful smoke test does not establish score reproduction.
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
17 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| attributes.comparison.adaptation Not reported Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.aggregation Not reported Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.budget Not reported Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.dataset_version Not reported Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.inputs Not reported Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.metric_implementation Source-defined endpoint; see result source_locator Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.population Erlangen MTB variants Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.protocol_id uc-clinical-20260930-oncovi-mtb-protocol Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.comparison.split Not reported Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | missing or unspecified No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.origin author_reported Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Results, Erlangen MTB variants Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded author reported Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
View linked audit checks and correction history
Release 2026-09-30-e37e3ab1284d · Record review: source checked
Stable ID: uc-clinical-20260930-oncovi-mtb-evaluation